Comparison of hypercalcemia between lanthanum carbonate and calcium carbonate in hyperphosphatemia patients on dialysis; a cross-over study

Comparison of hypercalcemia between lanthanum carbonate and calcium carbonate in hyperphosphatemia patients on dialysis; a cross-over study - Comparison of hypercalcemia between lanthanum carbonate and calcium carbonate

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002331

Enrollment

Registered

2009-08-17

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis patients with hyperphosphatemia

Interventions

Lanthanum carbonatet to Calcium carbonate Calcium carbonate to Lanthanum carbonate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hyperphosphatemia patients on hemodialysis (dialysis: more than 3 months) receiveing phosphate binders

Exclusion criteria

Exclusion criteria: 1) Pts with cancer or suspicious for cancer, Pts with inflammatory disorder 2) Pts who meet the contraindiation criteria in package insert of lanthanum carbonate or calcium carbonate 3) Pregnant or possibly pregnant pts, pts on lactation 4) Inappropriate pts for this study according to the investigator's judgment

Design outcomes

Primary

Measure	Time frame
The incidence of hypercalcemia for 3 months between lanthanum carbonate and calcium carbonate treatments.	—

Secondary

Measure	Time frame
1. Serum phosphate, serum calcium and serum albumin 2. Adverse events 3. Inflammation markets	—

Countries

Japan

Contacts

Public ContactTatsunori toida

Chiyoda Hospital Internal medicine

0982527111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026